For US Healthcare Professionals Only
Publications
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.
*Includes seizure clusters and acute or prolonged seizures
191 result(s)
phase
4/RWE
FINTEPLA® (fenfluramine)
Dravet Syndrome, Lennox-Gastaut Syndrome
Prolonged fenfluramine use in open-label studies of Dravet or Lennox-Gastaut syndromes: long-term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness
phase
4/RWE
FINTEPLA® (fenfluramine)
Dravet Syndrome
Healthcare resource utilization and persistence in children and adults with Dravet syndrome receiving fenfluramine: a retrospective analysis using United States claims data
phase
4/RWE
Generalized Myasthenia Gravis
Advancing Care in Myasthenia Gravis: What Can We Learn From the Multiple Sclerosis Community?
phase
4/RWE
Generalized Myasthenia Gravis
ENGAGE: Analyzing the value of virtual reality in a patient-centric immersive learning program in myasthenia gravis for healthcare professionals
pre-clinical
Generalized Myasthenia Gravis
Human in vitro neuromuscular junction model to functionally dissect the pathogenic mechanism of anti-AChR autoantibody-positive myasthenia gravis
pre-clinical
ZILBRYSQ® (zilucoplan)
Generalized Myasthenia Gravis
Discovery of Zilucoplan: A Complement C5 Inhibitor for Treatment of Anti-Acetylcholine Receptor (AChR) Antibody-Positive Generalized Myasthenia Gravis (gMG)
phase
3
BIMZELX® (bimekizumab-bkzx)
Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies
phase
3
BIMZELX® (bimekizumab-bkzx)
Hidradenitis Suppurativa
Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension
BIMZELX® (bimekizumab-bkzx)
Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis, Psoriatic Arthritis
Human spinal enthesis comparative biology of IL-17F and IL-17A reveals greater T-cell IL-17F induction and IL-23 regulation